Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 22, 2025
Discovery & Translation
Science Spotlight: Bacterial payload delivery from nose to brain
BioCentury’s roundup of translational innovations also includes targeting MSH3 to slow repeat expansion in Huntington’s; plus AAVs for kidney and T cells
BioCentury | Dec 4, 2023
Product Development
Early signs Alto’s precision neuropsychiatry approach may be working
Readout in major depressive disorder lends further support to biotech’s biomarker-driven patient selection strategy
BioCentury | Nov 21, 2023
Deals
Nov. 21 Quick Takes: Merck buying neurology play Caraway
Plus: Simcere takes Greater China rights to Connect’s IL-4R program, and updates from BeiGene, Ensem, J&J, Genmab, Alto, Ascendis and more
BioCentury | Feb 22, 2023
Deals
REGN scores P&G top dollar
As “creative” deals become a buzzword, BioCentury looks back at a 1997 deal that helped keep Regeneron independent
BioCentury | Jan 11, 2023
Deals
Jan. 10 Quick Takes: AbbVie taps Anima for mRNA therapeutics
Plus updates from Alto, Union, AskBio-Recode, Phathom and more
BioCentury | Nov 2, 2022
Emerging Company Profile
ProJenX: protecting neurons to treat ALS
Project ALS and Medical Excellence-backed company hopes to take same regulatory path forged by Amylyx
BioCentury | Oct 25, 2022
Regulation
Oct. 25 Quick Takes: FDA approves J&J’s Tecvayli, first bispecific T cell engager for MM
Plus: Novartis prunes programs and updates from Ipsen, Biogen, Astellas-Taysha, Alto, AZ and more
BioCentury | Aug 2, 2022
Finance
Aug. 1 Quick Takes: Qiming, Quan lead $120M series B for OriCell
Plus Concert preps JAK1/2 NDA and updates from Otonomy, Stealth and more
BioCentury | Apr 20, 2022
Data Byte
Colitis innovation in the Distillery spotlight
Targets include LRH-1, PYK2, BDNF, HSF1, ZDHHC7, LYPLA2 and cGas
Items per page:
1 - 10 of 158